Chapter 255: Ibetumomab becomes popular overseas
An hour later, the dinner was over.

It has to be said that Zhang Yang was quite surprised by Minako’s conversation and knowledge.

Originally, she thought that Friedman was only introducing a vase to her, but unexpectedly, Minako not only had a deep understanding of Chinese and Japanese culture, but also had her own insights into the field of drug research and development. For a while, the two of them had endless topics to talk about, and the atmosphere of the whole dinner was very harmonious.

Even until the end of the dinner, Zhang Yang still felt a little unsatisfied.

“Mr. Zhang, can I walk with you after dinner?”

“it is good.”

Zhang Yang did not refuse.

After they walked out of the Chinese restaurant, the lights began to dim, and the two walked all the way to the Hilton Hotel where Minako was staying.

The night breeze gently caressed Minako’s face, and the lights at the hotel entrance illuminated her even more.

“Mr. Zhang, would you like to go up and sit for a while and have a cup of tea before leaving?”

“No.”

This time Zhang Yang shook his head. He knew very well that their relationship was not that close yet.

Minako seemed to have expected Zhang Yang to refuse, and smiled:

“Then I’ll take you to the car first.”

“It’s okay, I can just take a taxi home.”

After a while, a yellow taxi stopped at the entrance of the hotel. After watching Zhang Yang leave, Minako let out a long breath and turned to walk into the hotel.

……

Although Minako left a good impression on Zhang Yang, it was just a small episode.

In the next two days, Zhang Yang quickly put this matter behind him and began to think about his next work focus.

Currently, the clinical trial of “Ivacumab” has come to an end, but the P4 biological laboratory will be built soon. Should we start allocating manpower to study the “T14 pneumonia virus”?

correct,

There is also the matter of Prince Amir of the Saudi royal family.

I received 50 billion US dollars and was promised to develop a drug that can completely cure hemophilia. Now the R&D team is almost set up. Should I participate in it and push forward the progress of the project?

While Zhang Yang was hesitating, he didn’t expect that the impact of the combined treatment with “ibumazumab” was not over yet.

overseas.

Leukemia Patient Alliance.

When Ibetuzumab was just undergoing clinical trials, foreign patients were very concerned about the progress of Ibetuzumab.

When the combined treatment regimen later triggered the side effect of bone marrow failure, many overseas patients were very worried that the clinical trial of “Ibetuzumab” would fail and could not continue.

At this time, the clinical trial of “Ibetuzumab” was resumed, and all overseas leukemia patients breathed a sigh of relief.

At the same time, the envy and jealousy hidden in my heart surged up again.

“I don’t understand.”

“Why can’t our country have a pharmaceutical company like Qingshan Pharmaceutical? Why can’t we receive clinical trials of such top-notch drugs?”

“I don’t understand either. What’s wrong with our country? What’s wrong with our government? Our society is sick.”

“Oh, I really want to go to China. I love this country. Can anyone tell me how to get to China and how to use Qingshan Pharmaceutical’s ‘Ibeumab’?”

“I also want to use Qingshan Pharmaceutical’s ‘Ibeumab’. Who wouldn’t want to?! The basic treatment rate is 83%. Maybe I can even reach more than 95%!”

“I’m so envious of the leukemia patients in China. They are much luckier than us because they have Qingshan Pharmaceutical!”

“Yes, to answer the question above, it is not difficult to get a visa to China. There is a 144-hour transit visa now. What is difficult is how can we get a place in the clinical trial! As far as I know, there are many leukemia patients in China, and many people are waiting for a place!”

“Oh, I see… We should call on the government to quickly bring in Qingshan Pharmaceutical. Doesn’t Qingshan Pharmaceutical deserve to have a branch in Europe?”

“Yes! I suggest that the government give Qingshan Pharmaceutical the best conditions to bring them in. Only then can we be saved!”

There are all kinds of opinions in the Overseas Leukemia Alliance.

However, some people are calling for action, while others are starting to take action.

In a beautiful villa in New York.

Huang Jinsong is a top expert in the chip field. He began to immerse himself in the semiconductor industry as early as the 1990s. More than 30 years have passed, and he has unknowingly become a leader in the industry.

Looking at the news on the computer screen about Qingshan Pharmaceutical’s “Ibetuzumab” solving side effects and reopening clinical trials, he thought for a long time, and finally took out his mobile phone slowly, found a number in the address book and dialed it.

As soon as the ringtone sounded, the phone was connected instantly, followed by an excited voice.

“Hello, Mr. Huang, have you thought it through? Are you willing to join our team?”

Huang Jinsong exhaled gently and nodded:

“Well, I’ve thought about it for a long time, and I agree to join Huawei and assist you in developing the latest generation of chips.”

There was an even more excited voice coming from the other end of the phone.

“Okay, okay, I finally got you!”

“Don’t worry, the shares and positions we mentioned to you earlier are all reserved for you. Once you return to China, you only need to sign and it will take effect immediately.”

Huang Jinsong couldn’t help but shake his head. Even through the phone, he could sense that this was not what he valued most:
“Thank you.”

“But before I return to my country to start work, I have a simple request that I hope you can help me with.”

Huang Jinsong paused as he spoke:
“My daughter was unfortunately diagnosed with ‘acute myeloid leukemia’ last year, and she relapsed after a bone marrow transplant two months ago.”

“I don’t want her to undergo a second bone marrow transplant at the moment… I saw on the Internet that China’s top pharmaceutical company Qingshan Pharmaceutical has recently developed a drug that can treat acute leukemia, and the published clinical trial results are very good…”

“So I want you to contact Qingshan Pharmaceutical and help my daughter get a place in a clinical trial!”

“As long as you agree to this condition, I can return to China tomorrow.”

The middle-aged man on the other end of the phone was obviously surprised.

He knew Qingshan Pharmaceutical, but didn’t know what the so-called drug for treating leukemia was.

“Mr. Huang, please wait a moment. I will write down your request!”

“Don’t worry, no matter what, we will do our best to apply for a clinical position for your daughter!”

Huang Jinsong finally showed a smile on his face, and his tone relaxed for the first time.

“Okay, then I’ll wait for your good news.”

“I still say the same thing. I agree to join Huawei, but I hope you can also help me contact Qingshan Pharmaceutical to solve the problem of clinical trial quotas!
“Okay, I’ll reply to you by tomorrow noon at the latest.”…

Early the next morning.

As soon as Zhang Yang arrived at the company, he learned from his assistant Xiao Chen that two CEOs who had just rushed over from Shenzhen were waiting in the reception room.

Also accompanying him was an office director from the city.

He was a little surprised, and walked quickly to the reception room, and said directly without any politeness:

“You two are…”

“Mr. Zhang! Excuse me for disturbing you. I am the head of a department at Huawei. My last name is Lu, Lu Xing. I am mainly responsible for some market outreach work at Huawei.”

“This guy’s surname is Ma, Ma Rengang, and he’s the general manager of our human resources department.”

Marketing department, human resources department?
Zhang Yang was even more confused, but when Lu Xing from the marketing department explained the purpose of this trip, his confusion turned into surprise.

“So the two of you came here this time hoping that we can open a back door and give a clinical trial quota to the daughter of your CEO who has not yet taken office?”

“Yes!” Ma Rengang nodded eagerly.

Zhang Yang pondered for a moment, frowned and said:
“It’s not impossible! It’s just that… our quota for Phase II clinical trial subjects is full.”

Before he finished speaking, the marketing manager Lu Xing beside him had already understood what he meant and said hurriedly:
“Don’t worry, Mr. Zhang!”

“Although Huawei and your company rarely have business overlap, I did my homework before coming here.”

“You may have heard that many foreign pharmaceutical companies have introduced AI intelligence and applied it to the screening of innovative drug compounds. Huawei happens to have certain technical reserves in this regard.”

“In the future, if you and Qingshan Pharmaceutical need it, we will definitely do our best to help your company build an AI model.”

Zhang Yang was stunned. He didn’t actually mean that originally.

Because the clinical trial plan itself is to first formulate a clinical trial number plan, and then recruit subjects, everything has detailed regulations!

but.

Now that Lu Xing had said this, it was impossible for him to refuse.

His brows relaxed slightly and a smile appeared on his face.

“Well, since Mr. Lu and Mr. Ma have come personally, we have no choice but to give them some convenience.”

“How about this? I’ll make a report to the review center and tell them that we have a special patient who needs to participate in independent medication. We’ll use the quota for independent medication to conduct clinical trials!”

Upon hearing this, Mr. Lu and Mr. Ma from Huawei nodded continuously.

They don’t care what method Zhang Yang uses, as long as they agree.

“Okay, okay, okay! Thank you so much, Mr. Zhang!”

……

Ordinary patients try every possible means to get a place in the clinical trial of “ibukumab”.

The global hematology industry.

Royal London Hospital, UK.

As early as when “Ibetuzumab” just participated in clinical trials, Richard, chief doctor of the Department of Hematology, flew to Chengdu Third People’s Hospital to learn about the actual clinical trial results of “Ibetuzumab”.

After returning, he wrote two papers on the clinical effects of “Ibetumumab” in one go, which received praise and inquiries from many colleagues.

When he heard that “ibumabucil” had the side effect of bone marrow failure, he was not too surprised, because he had discussed the possibility of side effects with Director Hu when he was at the Chengdu Third People’s Hospital.

On the contrary, he was quite surprised that Qingshan Pharmaceutical’s use of “ITG human myelopoietin” could cure the side effects so easily.

After the news was confirmed, he could no longer sit still.

“No, I have to go to China again!”

“Their combined treatment plan is now much more mature than when I went there before, and the results have been significantly improved!”

“Now that the side effects have been resolved, I must go back to China as soon as possible to learn the latest treatment options. Only in this way can I bring the latest leukemia treatment options back to Europe!”

“Are you going again?”

In the office, the doctors looked at Dr. Richard with envy.

Dr. Richard is well-known among hematologists around the world. That is why only he can travel to China at will and has the resources to exchange and study in the best hematology department in China.

I’m afraid I’ll have to write a lot of papers when I come back.

Everyone was envious and a little jealous.

At this moment, a doctor’s surprised voice suddenly sounded in the office!

“Dr. Richard, look in the group, Director Hu from the Huaxia Rongcheng Third People’s Hospital, yes! That’s the director of the hospital you visited before in Huaxia!”

“He just published a paper on ‘ibumab’, the name is …”

“Oh, MyGOD! The name of the paper is actually in Chinese, which translates to: ‘Study on the molecular mechanism of formation of allogeneic T cell immune synapse induced by Ibexin’!”
Moreover, the paper was not published in the Lancet’s hematology issue, but in a Chinese medical journal of its own!”

Dr. Richard was shocked and quickly took the tablet from his colleague.

After a quick glance, he suddenly took a few deep breaths:
“Whatever I say comes true!”

“I said last time that things change over time. Previously, Chinese doctors tried their best to learn our most advanced blood disease treatment plans.”

“But now it’s our turn to learn from them!”

“Look, now the most important leukemia treatment plans and treatment data papers in the Department of Hematology are all in Chinese and published in the Chinese journal ‘Hua Xia Frontier Medicine’!”

“They won’t submit to any of the Lancet or New England Journal of Medicine anymore!”

“This means that if we want to learn the latest leukemia treatment plans and data, we must learn Chinese. In the future, when we write papers, we will inevitably have to read these top papers in the journal ‘Hua Xia Frontier Medicine’!”

“They will even be cited extensively as literature!”

As he spoke, Richard suddenly felt inexplicably sad.

He shrugged and sighed:
“Shit, why do I suddenly feel that the center of future medicine will shift to the East?!”

“China is now the best country in the world in the treatment of blood diseases. So what disease will be treated next?!”

……

While Dr. Richard was sighing, on the other side,
Zhang Yang of Qingshan Pharmaceutical unexpectedly received a special invitation letter.

The sender of the invitation letter is none other than China Frontier Medical Journal.

(End of this chapter)